Dipeptidyl peptidase 4 (DPP-4)
Dipeptidyl peptidase 4 (DPP-4), also known as CD26 or adenosine deaminase complexing protein 2, is a serine protease and type II transmembrane glycoprotein expressed across many tissues, including the kidney, liver, intestine, immune cells, and vascular endothelium.
Dipeptidyl peptidase 4 (DPP-4), also known as CD26 or adenosine deaminase complexing protein 2, is a serine protease and type II transmembrane glycoprotein expressed across many tissues, including the kidney, liver, intestine, immune cells, and vascular endothelium. It also circulates in a soluble form shed from cell membranes. Its enzymatic function is to cleave dipeptides from the N-terminus of peptides that carry a proline or alanine at the penultimate position, an activity that lets it regulate the availability of numerous bioactive peptides. Most prominently, DPP-4 rapidly inactivates the incretin hormone glucagon-like peptide-1 (GLP-1), truncating it within minutes of its release from intestinal L-cells and thereby blunting its insulinotropic effect on postprandial glucose control. Because of this, elevated or unchecked DPP-4 activity is regarded as an aggravating factor in the progression of type 2 diabetes, and DPP-4 expression and activity are frequently increased in the setting of obesity and insulin resistance.
This substrate-truncating mechanism makes DPP-4 a validated pharmacological target. The "gliptin" class of orally administered inhibitors — including sitagliptin, vildagliptin, saxagliptin, and linagliptin — blocks the enzyme's active site, prolonging endogenous GLP-1 signaling to improve glycemic control in type 2 diabetes, and newer strategies such as PROTAC-mediated targeted degradation aim to achieve more sustained suppression than reversible inhibition allows. Beyond glucose homeostasis, DPP-4 and its inhibition are being examined in a widening range of contexts: coronary microvascular function and cardiovascular disease, bone metabolism and cellular senescence, where DPP-4 has been linked to ferroptosis in bone marrow stromal cells, neurodegenerative and diabetes-associated cognitive pathology, and even primary ovarian failure. These connections reflect the breadth of DPP-4's substrates and its intersections with oxidative stress, inflammatory signaling involving mediators such as Tnf-α, and iron-dependent cell death pathways.
Where the papers sit
9 papers from the last 6 months study Dipeptidyl peptidase 4 (DPP-4) directly · updated from PubMed 9 Nov 2026
Study type 0 clinical trials · 1 observational · 2 human data · 4 preclinical · 2 unclassified
Themes no clear themes
Those 9 do not share a common subject.
-
DPP-4 research here ranges from inhibitor discovery and enzyme profiling to disease associations in diabetes, psoriasis, infection and ovarian failure. Recurring work targets enzymatic inhibition through natural products, peptide prediction, dual inhibitors and PROTAC-mediated degradation. Other studies examine DPP-4 abundance, genetic links or disease mechanisms without a shared therapeutic endpoint. The cluster has no coherent direction beyond broad interest in DPP-4 as a biological and pharmacological target.
Papers
The 9 papers from the last 6 months that study Dipeptidyl peptidase 4 (DPP-4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- Bilingua-DPP-IV: A Bimodal Fusion Convolutional Neural Network Model for Prediction of Dipeptidyl Peptidase IV Inhibitory Peptides. ChemMedChem · 24 Oct 2026 PMID 42920236
- Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
- Multi-Omics Evidence from Genetics Reveals an Association between the Hypoglycemic Drug Target DPP4 and Primary Ovarian Failure. Omics : a journal of integrative biology · 22 Jul 2026 PMID 42484070
- Dipeptidyl peptidase IV contributes to the pathogenesis of Cryptococcus neoformans. mBio · 20 Jul 2026 PMID 42474189
- Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease. Rheumatology (Oxford, England) · 13 Jul 2026 PMID 42438152
- Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
- Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species. Journal of medicinal chemistry · 24 Jun 2026 PMID 42342236
- PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes. Journal of medicinal chemistry · 8 Jun 2026 PMID 42260272
- Design, synthesis, and inhibition of oxidative, amyloidogenic, and cholinergic dysfunction of saxagliptin-derived schiff bases against STZ-induced sporadic AD-like pathology. European journal of pharmacology · 24 May 2026 PMID 42178013
By study type
Observational studies and case reports (1)
- Examining the role of dipeptidyl peptidase IV (DPPIV) in psoriatic disease. Rheumatology (Oxford, England) · 13 Jul 2026 PMID 42438152
Human data, design not indexed (2)
- Bilingua-DPP-IV: A Bimodal Fusion Convolutional Neural Network Model for Prediction of Dipeptidyl Peptidase IV Inhibitory Peptides. ChemMedChem · 24 Oct 2026 PMID 42920236
- Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
Preclinical: animal, cell and lab studies (4)
- Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
- Dipeptidyl peptidase IV contributes to the pathogenesis of Cryptococcus neoformans. mBio · 20 Jul 2026 PMID 42474189
- Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species. Journal of medicinal chemistry · 24 Jun 2026 PMID 42342236
- Design, synthesis, and inhibition of oxidative, amyloidogenic, and cholinergic dysfunction of saxagliptin-derived schiff bases against STZ-induced sporadic AD-like pathology. European journal of pharmacology · 24 May 2026 PMID 42178013
Unclassified: not yet indexed with MeSH (2)
- Multi-Omics Evidence from Genetics Reveals an Association between the Hypoglycemic Drug Target DPP4 and Primary Ovarian Failure. Omics : a journal of integrative biology · 22 Jul 2026 PMID 42484070
- PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes. Journal of medicinal chemistry · 8 Jun 2026 PMID 42260272
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-02 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.